| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate |
2018-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102122546-B1 |
| titleOfInvention |
Natural killer cell expressing anti-cotinine chimeric antigen receptor specifically binding to cotinine |
| abstract |
The present invention relates to natural killer cells expressing an anti-cortinine chimeric antigen receptor (CAR) that specifically binds to cotinine and a cell therapeutic agent comprising the same. Natural killer cells expressing a chimeric antigen receptor that specifically binds to cotinine according to the present invention can effectively migrate to tumor tissue regardless of the type of cancer, depending on the conjugated substance conjugated to cotinine, and thus Killer cells can be usefully used as a gene therapy for high-efficiency anti-cancer effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220148745-A |
| priorityDate |
2017-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |